Dova Pharmaceuticals, Inc. Common Stock
DOVA
DOVA was delisted on the 11th of November, 2019.
39 hedge funds and large institutions have $160M invested in Dova Pharmaceuticals, Inc. Common Stock in 2017 Q3 according to their latest regulatory filings, with 21 funds opening new positions, 10 increasing their positions, 4 reducing their positions, and 12 closing their positions.
150% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 4
75% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 12
30% more funds holding
Funds holding: 30 → 39 (+9)
19% more capital invested
Capital invested by funds: $135M → $160M (+$25.3M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NC
Nexthera Capital
New York
|
+$5.69M |
| 2 |
BlackRock
New York
|
+$5.42M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.54M |
| 4 |
Wells Fargo
San Francisco,
California
|
+$2.95M |
| 5 |
PC
Pier Capital
Stamford,
Connecticut
|
+$1.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
-$2.23M |
| 2 |
PC
Paulson & Co
New York
|
-$1.68M |
| 3 |
PWAM
Park West Asset Management
San Francisco,
California
|
-$1.34M |
| 4 |
Millennium Management
New York
|
-$1.05M |
| 5 |
OA
Omega Advisors
New York
|
-$892K |
DOVA Hedge Fund Activity: Q3 2017 in Review
39 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Dova Pharmaceuticals, Inc. Common Stock (DOVA) for Q3 2017, worth a combined $160M — up 19% from $135M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new DOVA positions and 12 closed out — a net gain of 9 holders — while 10 added to existing stakes and 4 trimmed.
The largest buyer was Nexthera Capital, adding an estimated $5.69M. The largest seller was Monashee Investment Management, exiting entirely with an estimated $2.23M sold.
- 39 institutional investors held Dova Pharmaceuticals, Inc. Common Stock (DOVA) as of Q3 2017, up from 30 in Q2 2017.
- Funds reported $160M of Dova Pharmaceuticals, Inc. Common Stock stock for Q3 2017, up 19% quarter-over-quarter.
- 21 funds opened new Dova Pharmaceuticals, Inc. Common Stock positions in Q3 2017 and 12 closed out, a net change of +9 holders.
- The largest Dova Pharmaceuticals, Inc. Common Stock buyer in Q3 2017 was Nexthera Capital, an estimated $5.69M added.
- The largest Dova Pharmaceuticals, Inc. Common Stock seller in Q3 2017 was Monashee Investment Management, an estimated $2.23M sold.
Based on aggregated 13F filings for Q3 2017.